Long way for any significant financing to arrive IMHO. Even longer to resume ampakine trials, and longer still for NAS listing attempts, as any success in trials will be immediately diluted down to raise cash. Will be hard to take any profits due to thinly traded nature of this poor little rascal of a stock. Wish things were different, but it's hard to reverse decades of past mismanagement, lies and missed opportunities by Stoll, and Varney. R&R once offered the equivalent of $400 per share figuring in the reverse split, Stoll angrily accused them of "trying to steal" his company.
News 
Market Data 
Discover 
